Form 4: RA Capital Management Acquires Stock Options in Werewolf Therapeutics

RA Capital Management, along with related entities and individuals, reports the acquisition of stock options in Werewolf Therapeutics.

Summary

• RA Capital Management, L.P., along with related entities and individuals including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev Shah, filed a Form 4.
• The filing reports the acquisition of 17,500 stock options in Werewolf Therapeutics, Inc. (HOWL) on May 24, 2024.
• The exercise price of the options is $4.88.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on Derek DiRocco's continued service as a director.
• The options expire on May 23, 2034.
• Derek DiRocco, a Partner of the Adviser, holds the option for the benefit of the Fund and the Nexus Fund II and is obligated to turn over any net cash or stock received upon exercise of the option to offset advisory fees.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard filing related to stock option grants, indicating routine investment activity.

Industry Context

This filing reflects investment activity in the biotechnology sector, specifically in Werewolf Therapeutics (HOWL). RA Capital Management's investment suggests confidence in the company's prospects.

Stakeholder Impact

• The acquisition of stock options by RA Capital Management may signal confidence in Werewolf Therapeutics, potentially impacting shareholder sentiment positively.

Key Dates